T-DXd is now approved for the 1L cytotoxic treatment of patients with HR+/HER2-low or #ultralow MBC, based on the results of DB06. Best suited in this 1L setting for pts with visceral and aggressive disease. Next step: unlocking the full spectrum of HER2.